oral glp 1 agonist new In the ATTAIN-1 phase 3, randomized trial, the use of orforglipron GLP-1 Agonists For Obesity In
Description
2025;19(4):jjae160
doi: 10.1038/nature22378 [DOI] [PubMed] [Google Scholar] 82.Baggio LL, Yusta B, Mulvihill EE, et al
Yazici D, Yapici Eser H, Kiyici S, Sancak S, Sezer H, Uygur M, et al
Visit nuvancehealth.org for more information.
Alternatives to microdosing There are some safer and evidence-based alternatives to microdosing
